NCT Number: NCT06620068
This study aims to investigate the causal relationship between plasma vascular endothelial growth factor (VEGF) family proteins and placenta previa using a two-sample Mendelian randomization (MR) approach. Genome-wide association study (GWAS) data will be analyzed to assess the correlation and potential causality between VEGF protein levels and the occurrence of placenta previa.
Trial opening soon.
Get NotifiedAll sexes
Observational
Placenta previa is a serious complication during pregnancy, leading to significant risks for both the mother and the fetus. This study utilizes Mendelian randomization (MR) to explore the potential causal link between plasma levels of VEGF family proteins (including VEGFA, VEGFB, VEGFC, VEGFD, and PLGF) and the risk of placenta previa. By using genome-wide association study (GWAS) data from the UK Biobank and FinnGen datasets, the study aims to provide insights into the role of angiogenesis and abnormal placental development. The MR analysis will help minimize confounding factors and provide robust evidence regarding the causal relationship between VEGF proteins and placenta previa.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: Data analysis and outcome assessment will be completed by December 2024
This outcome measures the association between plasma VEGFA levels (measured in picograms per milliliter) and the occurrence of placenta previa, using Mendelian Randomization (MR) analysis to assess causality.
Time frame: Data analysis and outcome assessment will be completed by December 2024
This outcome measures the association between plasma VEGFB levels (measured in picograms per milliliter) and the occurrence of placenta previa, using Mendelian Randomization (MR) analysis to assess causality.
Time frame: Data analysis and outcome assessment will be completed by December 2024
This outcome measures the association between plasma VEGFC levels (measured in picograms per milliliter) and the occurrence of placenta previa, using Mendelian Randomization (MR) analysis to assess causality.
Time frame: Data analysis and outcome assessment will be completed by December 2024
This outcome measures the association between plasma PLGF levels (measured in picograms per milliliter) and the occurrence of placenta previa, using Mendelian Randomization (MR) analysis to assess causality.
Contact information is provided by the study sponsor or research team.
Guangzhou Institute of Respiratory Disease
Other
Causal Association Between Plasma Vascular Endothelial Growth Factor Family Proteins and Placenta Previa: A Two-Sample Mendelian Randomization Study
Acronym: VEGF PP
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01990625
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Death
Guatemala City, Guatemala
View Trial DetailsNCT07452185
Female Urogenital Diseases and Pregnancy Complications, Obstetric Labor Complications
View Trial DetailsNCT07423156
Diabetes Insipidus, Endocrine System Diseases
Lahore, Punjab Province, Pakistan
View Trial DetailsNCT06589180
Female Urogenital Diseases and Pregnancy Complications, Obstetric Labor Complications
View Trial Details